Press Releases

Chegg, Inc. (NYSE:CHGG), a global learning and workforce skilling company, today reported financial results for the quarter ended June 30, 2026. "In Q2 we outperformed our expectations on revenue, adjusted EBITDA, and cash, reflecting our ability to execute against our priorities while investing for future growth," said Dan Rosensweig, CEO and Executive Chairman of Chegg. "Our long-term goal remains the same: return Chegg to growth with high margins and strong free cash flow." Second Quarter 2026 Highlights Total Net Revenues of $51.8 million, a decrease of 51% year-over-year Chegg Skilling Revenues of $17.5 million, an increase of 2% year-over-year Gross Margin of 55% Non-G

Transaction Accelerates Portfolio Repositioning, Significantly Reduces Leverage and Enhances Investment Capacity BlackRock TCP Capital Corp. ("we," "us," "our," "TCPC" or the "Company"), a business development company (NASDAQ:TCPC), today announced its financial results for the second quarter ended June 30, 2026 and a $523 million portfolio sale transaction that meaningfully accelerates its ongoing efforts to strengthen its financial position and reshape its investment portfolio. SECOND QUARTER FINANCIAL HIGHLIGHTS On a GAAP basis, net investment income for the quarter ended June 30, 2026 was $18.1 million, or $0.22 per share on a diluted basis, which exceeded the regular dividend of

Charles River Associates (NASDAQ:CRAI), a worldwide leader in providing economic, financial, and management consulting services, today announced an increase and extension to its existing credit facility with a bank syndicate comprised of six lenders. The five-year credit facility is for an aggregate principal amount of up to $400 million, consisting of a $75 million term loan and a $325 million revolving credit facility. The revolving credit facility may be decreased at CRA’s option to $250 million for the period of July 16 to January 15 of each year, during which time CRA’s working capital needs are typically diminished. Additionally, for the period of January 16 to July 15 of each year, C

SAN DIEGO, Aug. 06, 2026 (GLOBE NEWSWIRE) -- VivoSim Labs, Inc. (NASDAQ:VIVS) (the "Company" or "VivoSim"), a provider of next-generation New Approach Methodologies (NAM) 3d human cellular models for preclinical safety, today announced that on August 4, 2026, we received notice from the Listing Qualifications Staff of The Nasdaq Stock Market LLC indicating that the Company has regained compliance with Nasdaq Listing Rule 5550(b)(1) which requires registrants to maintain a minimum stockholders’ equity of $2.5M. Subsequent to the filing of its recent Annual Report on Form 10-K for the fiscal year ended March 31, 2026, filed with the SEC on July 14, 2026 (the "Form 10-K"), the Company receiv

PLYMOUTH MEETING, Pa., Aug. 06, 2026 (GLOBE NEWSWIRE) -- Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY), today announced that Harmony's management team will participate in a fireside chat at the Piper Sandler Virtual CNS Symposium on Thursday, August 13, 2026, at 1:30 p.m. ET. A webcast of the fireside chat will be available on the investor page of the Harmony Biosciences website at https://ir.harmonybiosciences.com/. About Harmony BiosciencesHarmony Biosciences is a pharmaceutical company dedicated to developing and commercializing innovative therapies for patients with rare neurological diseases who have unmet medical needs. Driven by novel science, visionary thinking, and a commitme

Increases 2026 Revenue Guidance to a Range of $104M to $108M Conference Call Today at 8:30 a.m. Eastern Time Delcath Systems, Inc. (NASDAQ:DCTH), an interventional oncology company focused on the treatment of primary and metastatic liver cancers, today announced financial results and business highlights for the second quarter ended June 30, 2026. Second Quarter 2026 Financial Results Total revenue of $29.1 million, compared with $24.2 million in the second quarter of 2025 HEPZATO KIT™ revenue of $27.1 million, compared to $22.5 million in the second quarter of 2025 CHEMOSAT® revenue of $2.0 million, compared to $1.7 million in the second quarter of 2025 Gross margins of 90

Strong quarter led by AI momentum driving growth in cloud, infrastructure and services; Raising guidance for full year Insight Enterprises, Inc. (NASDAQ:NSIT) (the "Company") today reported financial results for the quarter ended June 30, 2026. Highlights include: Consolidated net sales increased 15% year over year Gross profit increased 18% year over year to $521.6 million and gross margin expanded 60 basis points to 21.7% Consolidated net earnings increased 65% year over year to $77.6 million Adjusted earnings before interest, tax, depreciation and amortization ("EBITDA") increased 29% year over year to $190.4 million Diluted earnings per share of $2.57 increased 76% year

First Quarter Revenue Increased 14% on a Reported Basis and 13% in Constant Currency, Ahead of Expectations, led by Asia and North America Global Direct-to-Consumer Comparable Store Sales Increased Low-Double-Digits, Driven By Both Digital and Brick-and-Mortar Retail Channels and 15% AUR Growth; Wholesale Sales Accelerated to Mid-Teens Growth on Healthy Underlying Demand Adjusted Gross and Operating Margin Expansion Exceeded Our Outlook, with Strong Full-Price Demand and Expense Discipline More Than Offsetting Increased Marketing Investments Maintained Healthy Balance Sheet Positioning with $1.9 Billion in Cash and Short-Term Investments and Inventories Well-Positioned to Globa

Houston, Texas--(Newsfile Corp. - August 6, 2026) - MultiSensor AI Holdings, Inc. (NASDAQ:MSAI) ("MultiSensor AI," "MSAI" or the "Company") plans to report financial results for the second quarter of 2026 on Thursday, August 13, 2026, after the U.S. stock market closes.About MultiSensor AIMultiSensor AI is a multi-sensor condition intelligence solution for high-throughput and highly automated industrial operations. By unifying thermal, vibration, and visual sensor data in a single solution, MultiSensor AI enables reliability teams to proactively protect uptime, reduce maintenance costs, enhance safety, and extend the useful life of their most critical assets. For more information, visit www.

HAMILTON, Bermuda, Aug. 6, 2026 /PRNewswire/ -- White Mountains Insurance Group, Ltd. (NYSE:WTM) reported book value per share of $2,258 as of June 30, 2026, an increase of 4% for the second quarter of 2026 and 3% for the first six months of 2026, including dividends. Liam Caffrey, CEO, commented, "Book value per share was up 4% in the quarter, driven by strong operating company results and solid investment returns.  Ark produced an 84% combined ratio and strong growth in tangible book value.  Kudu generated a 15% return on equity on a trailing 12 months basis, driven by strong growth on a same store basis coupled with sale transactions.  HG Global grew its book value by 1%, including a $90

FOX REPORTS FULL YEAR FISCAL 2026 REVENUE OF $17.13 BILLION, NET INCOME OF $1.73 BILLION, AND ADJUSTED EBITDA OF $3.91 BILLIONNEW YORK, Aug. 6, 2026 /PRNewswire/ -- Fox Corporation (NASDAQ:FOXA, FOX)) ("FOX" or the "Company") today reported financial results for the three and twelve months ended June 30, 2026.Commenting on the results, Executive Chair and Chief Executive Officer Lachlan Murdoch said:"Fiscal 2026 was an exceptional year for FOX, capped by our broadcast of a remarkable FIFA Men's World Cup. We successfully launched our direct-to-consumer streaming service, FOX One, continued to keep America informed across a dynamic news cycle, enhanced Tubi's position as a leading streaming s

Reported total revenue of $57 million for the second quarter of 2026 and raised full-year 2026 Revenue Framework Improved GAAP Combined R&D and SG&A expense guidance by $10 million at mid-point Sanofi confirmed with Novavax that they are in advanced discussions with regulators regarding their Phase 3 COVID-19-Influenza Combination trial timing and intend to be among the first movers in the combination vaccine segmentCompletion of manufacturing technology transfer to Sanofi expected in mid-2027 and would trigger a $75 million milestone payment to NovavaxMultiple partner-led experiments with Matrix-M are currently underway in a wide array of infectious disease and oncology targets On track to

Newly pending sales fell sharply from June as mortgage rates hit their highest point in a year, signaling that July's sales bump may not lastHome sales rose 7% year over year in July, the strongest annual gain of the year, according to Zillow's July Market Report. This largely represents transactions in which an offer was accepted in June.Newly pending listings, a leading indicator of future closings, grew just 0.3% from a year ago and fell 7.7% from June.Inventory sits 1.5% above year-ago levels, helped by 3.1% annual growth of new listings, extending the 32-month streak of supply gains.SEATTLE, Aug. 6, 2026 /PRNewswire/ -- Home sales surged 7% in July, the strongest annual gain seen so far

Advances Commercialization for Domestic LEU and HALEU Enrichment Contract includes X-energy prepayments to Centrus Planned project to bring clean energy investment and jobs to Eastern TennesseeBETHESDA, Md., Aug. 6, 2026 /PRNewswire/ -- Centrus Energy Corp. (NYSE:LEU) ("Centrus"), a trusted supplier of nuclear fuel, services and technology, today announced a signed definitive contract for Centrus to provide X-energy with enrichment services for Low-Enriched Uranium ("LEU") and High-Assay, Low-Enriched Uranium ("HALEU") with quantities that are expected to support X-energy's initial Xe-100 small modular reactors and TRISO-X fuel deployments. Under the contract, X-energy will provide prepaymen

NEW YORK, Aug. 6, 2026 /PRNewswire/ -- Burford Capital Limited ("Burford"), the leading global finance and asset management firm focused on law, today announces its unaudited financial results for the three and six months ended June 30, 2026 ("2Q26" and "YTD26", respectively). The full detailed presentation of Burford's 2Q26 and YTD26 financial results, as well as detailed portfolio data table, can be viewed at http://investors.burfordcapital.com. Christopher Bogart, Burford Capital's Chief Executive Officer, commented:"Burford generated more cash this quarter than any since the first quarter of 2025, and July saw strong momentum in the portfolio."With $733 million of cash on hand, Burford i

Latest accolade builds on last month's #1 ranking by US News & World Report; Wyndham Rewards Earner® Card named #1 Travel & Hotel Credit Card for eighth consecutive yearHIGHLIGHTSUSA TODAY readers voted Wyndham Rewards the No. 1 Hotel Loyalty Program for the ninth consecutive year, building on last month's No. 1 ranking from US News & World Report.Wyndham Rewards Earner® Card named the No. 1 Travel & Hotel Credit Card for the eighth consecutive year, following recent reimagining of co-branded credit card portfolio.The dual No. 1 rankings are a powerful endorsement of Wyndham Rewards' uncomplicated, high-value approach to loyalty, prioritizing simple fixed redemptions and generous rewards.PAR

Citrin Cooperman combines deep ERP implementation experience with strategic financial and operational advisory to help middle-market companies streamline operations, improve visibility, and accelerate growthIntuit Enterprise Suite delivers AI-native, enterprise-grade financial management and insights in a modern, scalable platform built for the middle marketNEW YORK, Aug. 6, 2026 /PRNewswire/ -- Citrin Cooperman Advisors LLC, the premier professional services provider for private, middle-market businesses and high-net-worth individuals, and Intuit Inc. (NASDAQ:INTU), the global financial technology platform that makes Intuit TurboTax, Credit Karma, QuickBooks, Mailchimp, and Intuit Enterpris

Phase 1 trials for HWK-007 and HWK-016 continue to enroll; the Phase 1 trial for HWK-206 is on track to initiate in Q3 2026Cash, cash equivalents and short-term investments of $190.0 million as of June 30, 2026, anticipated to fund operations into 2H 2028MORRISTOWN, N.J., Aug. 6, 2026 /PRNewswire/ -- Whitehawk Therapeutics, Inc. (NASDAQ:WHWK), a clinical-stage oncology therapeutics company applying advanced technologies to established tumor biology to efficiently deliver improved antibody drug conjugate (ADC) cancer treatments, today announced financial results for the quarter ended June 30, 2026, and provided recent corporate highlights."The second quarter saw meaningful progress for our th

–  Announced positive top-line data from 12-week Phase 2 CIRRUS-HCM trial with EDG-7500 in obstructive and nonobstructive hypertrophic cardiomyopathy (HCM) ––  Completed sale of sevasemten and muscular dystrophy business to Servier for up to $2.65 billion in July 2026, strengthening the balance sheet, sharpening focus on the cardiovascular pipeline –BOULDER, Colo., Aug. 6, 2026 /PRNewswire/ -- Edgewise Therapeutics, Inc. (NASDAQ:EWTX), a leading clinical-stage biopharmaceutical company focused on cardiovascular diseases, today reported financial results for the second quarter of 2026 and recent business highlights. "In the seco

Appointment builds on Providence's category leadership in Total Segmental Fusion (TSF)PLEASANTON, Calif., Aug. 6, 2026 /PRNewswire/ -- Providence Medical Technology, Inc., an innovator in differentiated spinal fusion technologies designed to improve patient outcomes, today announced that its Board of Directors has appointed Lane Major as President & Chief Executive Officer. Major also joins the company's Board of Directors. The appointment comes during a period of strong commercial momentum for Providence. Adoption of the flagship CORUS™ tissue-sparing fusion technology continues to grow across both the cervical and lumbar fusi